These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20216907)

  • 21. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
    Kong HH; Myers SA
    Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy.
    Alimenti A; Forbes JC; Oberlander TF; Money DM; Grunau RE; Papsdorf MP; Maan E; Cole LJ; Burdge DR
    Pediatrics; 2006 Oct; 118(4):e1139-45. PubMed ID: 16940166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Darunavir: after multiple antiretroviral treatment failure: another option.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18629967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacogenetics of antiretroviral therapy: a review of studies to date.
    Quirk E; McLeod H; Powderly W
    Clin Infect Dis; 2004 Jul; 39(1):98-106. PubMed ID: 15206060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics of HIV therapy.
    Owen A; Pirmohamed M; Khoo SH; Back DJ
    Pharmacogenet Genomics; 2006 Oct; 16(10):693-703. PubMed ID: 17001288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of human genetic variation on HIV disease in the era of HAART.
    Brumme ZL; Harrigan PR
    AIDS Rev; 2006; 8(2):78-87. PubMed ID: 16848275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding and managing the adverse effects of antiretroviral therapy.
    Hawkins T
    Antiviral Res; 2010 Jan; 85(1):201-9. PubMed ID: 19857521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.
    Wangsomboonsiri W; Mahasirimongkol S; Chantarangsu S; Kiertiburanakul S; Charoenyingwattana A; Komindr S; Thongnak C; Mushiroda T; Nakamura Y; Chantratita W; Sungkanuparph S
    Clin Infect Dis; 2010 Feb; 50(4):597-604. PubMed ID: 20073992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction-maintenance antiretroviral strategies to reduce long-term toxicity.
    Kelly M
    J HIV Ther; 2003 Feb; 8(1):11-4. PubMed ID: 12840709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacogenetics of antiretroviral therapy 2008: toward personalized treatment?].
    Vidal Marsal F
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():1-3. PubMed ID: 18680689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.